Evotec AG has licensed a portfolio of small molecules and biologics designed to trigger the regeneration of insulin-producing beta cells to Johnson & Johnson subsidiary Janssen Pharmaceuticals. The compounds were identified by Harvard University scientists in Douglas Melton’s lab and further analyzed in collaboration with Evotec as part of an R&D program with CureBeta.   Evotec will receive $8 million upfront and is eligible to receive certain preclinical, clinical, regulatory and commer...